Ultragenyx Pharmaceutical (RARE) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is RARE's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Ultragenyx Pharmaceutical (NASDAQ: RARE) expects to reach profitability in 2027 as it cuts spending, expands sales of existing rare-disease treatments and launches two gene therapies, executives said at the UBS Global Bi…

Ultragenyx Pharmaceutical Inc. (RARE) Presents at UBS Global Biopharma Conference 2026 Transcript…

I initiate coverage of Ultragenyx Pharmaceutical with a Hold rating and $18 price target, citing a credible valuation floor but limited near-term catalysts. Two major late-stage pipeline failures have reset investor sent…

NOVATO, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-…

BASEL, Switzerland, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialisation of novel therapies for rare and ultra-rare genetic diseases, to…

Ultragenyx Pharmaceutical remains a cautious 'Hold,' as profitability targets are driven by deep R&D cuts, not robust revenue growth. RARE's Q3 revenue rose 8% Y/Y to $173M, but business remains highly concentrated in CR…

Ultragenyx Pharmaceutical Inc. ( RARE ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Joshua Higa - Director of Investor Relations & Corporate Communications Emil Kakkis - Founder, President, CE…

Ultragenyx Pharmaceutical NASDAQ: RARE said its third quarter included two U.S. gene therapy approvals, a failed late-stage Angelman syndrome study, the termination of its Wilson disease program and restructuring actions…

Ultragenyx (RARE) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $1.81 per share a year ago.…

While the top- and bottom-line numbers for Ultragenyx (RARE) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street…

Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter Two Priority Review Vouchers (PRVs) unde…

NOVATO, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-r…

Phase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New Long-Term UPLIZNA Data in Ig…

Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.…

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE - Get Free Report) CFO Howard Horn sold 7,066 shares of the company's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $15.27, fo…

Ultragenyx agrees to sell its Fayuvi-linked PRV for $203 million, marking its second voucher sale in one week and adding non-dilutive funding for rare-disease programs.…

Ultragenyx's established rare-disease treatments continue to support revenue growth, while two newly approved gene therapies offer additional commercial opportunities.…

Agreement marks the Company's second PRV sale within one week, following the previously announced GENGLYCOS™ PRV transaction Agreement marks the Company's second PRV sale within one week, following the previously announc…

Atara Biotherapeutics (NASDAQ: ATRA - Get Free Report) and Ultragenyx Pharmaceutical (NASDAQ: RARE - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two comp…

RARE enters into an agreement to sell a Rare Pediatric Disease PRV for $210M, adding non-dilutive cash as it advances rare-disease therapies.…

Ultragenyx Pharmaceutical (NASDAQ:RARE) shares rose over 3.2% on Wednesday morning after the biopharmaceutical company agreed to sell a Rare Pediatric Disease Priority Review Voucher for $210 million. The voucher was awa…

NOVATO, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PR…

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to co…

BASEL, Switzerland, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Today Ultragenyx announced that the European Medicines Agency (EMA) has validated the Company's Marketing Authorisation Application (MAA) for its investigational gene…

NEW YORK, Oct. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact…
Kept in their own lane. A press release is the company talking, not reporting.
Expected by Feb 16. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

